The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Male or eligible female participants
Participants with >=40 to less than or equal to (<=) 80 years of age.
An eosinophilic phenotype with elevated BEC.
Moderate to very severe COPD with frequent exacerbations.
Current or prior physician diagnosis of asthma
Other clinically significant lung disease.
Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.